Kalvista Pharmaceuticals Inc (NASDAQ:KALV) insider Edward P. Feener sold 4,000 shares of the business’s stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $24.92, for a total value of $99,680.00. Following the completion of the sale, the insider now directly owns 100,950 shares of the company’s stock, valued at $2,515,674. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of KALV stock opened at $25.50 on Friday. Kalvista Pharmaceuticals Inc has a 52 week low of $7.73 and a 52 week high of $34.92.
Kalvista Pharmaceuticals (NASDAQ:KALV) last issued its earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.23) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.45) by $0.22. Kalvista Pharmaceuticals had a negative return on equity of 19.12% and a negative net margin of 70.08%. The company had revenue of $3.89 million during the quarter, compared to the consensus estimate of $3.97 million. On average, analysts anticipate that Kalvista Pharmaceuticals Inc will post -1.43 EPS for the current fiscal year.
A number of equities analysts have commented on KALV shares. Needham & Company LLC started coverage on Kalvista Pharmaceuticals in a research note on Wednesday, March 20th. They issued a “buy” rating and a $35.00 target price for the company. Zacks Investment Research upgraded Kalvista Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $26.00 target price for the company in a research note on Saturday, March 2nd. BidaskClub downgraded Kalvista Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 17th. Finally, ValuEngine upgraded Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, February 4th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $28.60.
A number of hedge funds have recently modified their holdings of KALV. Vanguard Group Inc boosted its stake in Kalvista Pharmaceuticals by 152.4% in the third quarter. Vanguard Group Inc now owns 296,581 shares of the specialty pharmaceutical company’s stock valued at $6,558,000 after acquiring an additional 179,092 shares during the period. Vanguard Group Inc. boosted its stake in Kalvista Pharmaceuticals by 152.4% in the third quarter. Vanguard Group Inc. now owns 296,581 shares of the specialty pharmaceutical company’s stock valued at $6,558,000 after acquiring an additional 179,092 shares during the period. Stonepine Capital Management LLC acquired a new position in shares of Kalvista Pharmaceuticals during the third quarter worth approximately $3,053,000. Fosun International Ltd acquired a new position in shares of Kalvista Pharmaceuticals during the fourth quarter worth approximately $2,444,000. Finally, Renaissance Technologies LLC boosted its position in shares of Kalvista Pharmaceuticals by 228.5% during the third quarter. Renaissance Technologies LLC now owns 117,349 shares of the specialty pharmaceutical company’s stock worth $2,595,000 after buying an additional 81,621 shares during the period. Institutional investors own 77.37% of the company’s stock.
Kalvista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Further Reading: Special Dividends
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.